Phase Ib sensorineural hearing loss trial
Frequency Therapeutics has dosed the first subject in the Phase Ib clinical trial of its hearing restoration candidate, FX-345, to treat sensorineural hearing loss (SNHL).
Named FX-345-101, the prospective, single-blind, two-cohort, randomized, placebo-controlled, multicentre trial will assess the safety of single intratympanic doses of FX-345.
It will enroll nearly 36 adult subjects aged 18 to 67 years with adult-onset acquired SNHL.
The preliminary safety cohort of the trial will have nine subjects to evaluate the safety and drug exposure versus a placebo.
On obtaining favorable safety data, the second cohort with 27 subjects will receive the treatment to further assess the safety.
It will also analyse if FX-345 boosts auditory function measures.
A cocktail of two small molecules, FX-345 is created for restoring inner ear cells required for hearing.
Frequency Therapeutics CEO David Lucchino said: “Advancing FX-345 to the clinic is an exciting milestone, as we further our pioneering work to develop regenerative therapeutics for hearing loss.
“By expanding our hearing pipeline, we hope to better understand the breadth of SNHL types and severities, we may be able to treat, and we look forward to FX-345 Phase Ib study data in the second half of next year.”
Apart from FX-345, the company is analyzing a therapeutic candidate, FX-322, in a Phase IIb trial underway for SNHL.
The double-blinded, randomized, placebo-controlled, multicentre trial is intended to assess the efficacy of FX-322 on speech perception in participants aged 18 to 65 years, with hearing loss linked to either noise-induced or permanent idiopathic sudden SNHL.